EpiVax, Inc.: Open Registration for Spring 2010 URI Class

News

EpiVax, Roche Team Up to Develop Tregitope Technology - December 2009

EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology - December 2009

Providence’s Jewelry District: Growth hotspot? - November 2009

Polly Matzinger Fearless Scientist Award - November 2009

Boston Herald Business News: Annie De Groot Proves the Power of One Person - October 2009

Open Registration for Spring 2010 URI Class - September 2009

EpiVax, De Groot focus of WRNI feature on biotech and the "knowledge economy" - August 2009

Cicilline cites EpiVax as socially-conscious company - August 2009

Mass High Tech Business News: De Groot wins $13M NIH Grant - July 2009

Providence Business News: De Groot wins $13M NIH grant - July 2009

Providence Journal: URI wins $13-million federal grant for vaccine research - July 2009

URI researcher awarded $13 million grant for development of vaccines for emerging infectious diseases - July 2009

EpiVax Research to be Presented at Numerous Conferences this Autumn - July 2009

Providence Business News profiles Dr. Anne De Groot - June 2009

Dr. De Groot honored at PBN Business Women Awards luncheon - May 2009

Dr. Anne De Groot Appears on "Amazing Women" Radio Show - May 2009

Annie De Groot Presents to NIH/NIAID on Next Generation Epitope-Driven Vaccines - May 2009

Dr. Annie De Groot chosen for PBN Overall Career Achievement Award - April 2009

Daughter, Father Reunite at URI Lab - February 2009

New lab will research vaccines - February 2009

URI taps De Groot to head new vaccine research center - February 2009

EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery - December 2008

EpiVax Profiled as "Tech Firm in RI to Watch" - November 2008

EpiVax Receives Tech Citizenship Award from Mass High Tech - October 2008

Publication on “Tregitopes” in Blood Journal of October 2008 - October 2008

Dr. Annie De Groot, CEO, awarded YWCA 2008 Women of Achievement Award - September 2008

EpiVax awarded $35K Montel Williams Foundation grant for multiple sclerosis research - September 2008

EpiVax Recieves $600,000 NIH Grant to Further Research in Type 1 Diabetes - September 2008

EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference - January 2008

EpiVax Receives JDRF Industry Program Funding to Develop Diabetes Drug Using Natural "regulatory" T cells - October 2007

EpiVax awarded $590,000 SBIR for Immunoinformatics-driven TB Vaccine - September 2007

EpiVax Awarded a Grant for Hemophilia Therapy - July 2007

EpiVax funded to advance research on a new, improved “Botox” - March 2007

EpiVax wins SBIR Phase I grant totaling $993,771 to Develop Smallpox Vaccine - June 2005

EpiVax Is Awarded H. Pylori SBIR Grant by National Institutes of Health - June 2005

EpiVax moves to new facility at 146 Clifford Street including office and laboratory space - November 2004

EpiVax wins SBIR Phase I grant totaling $859,773 to Develop Tularemia Vaccine - September 2004

EpiVax signs Master Services Agreement with Amgen - July 2004

EpiVax renews technology license with Brown University - August 2003

EpiVax receives $150,000 in phase II funding from Slater Center for Bio-Technology - March 2003

EpiVax signs Master Services Agreement with Brown University - March 2003

EpiVax signs Laboratory Services Agreement with Eli Lilly - March 2002

Awarded SBIR Phase I grant for West Nile Virus diagnostic project - September 2001

Awarded SBIR Phase I grant for Human Papiloma Virus vaccine project - September 2001

Signed strategic cooperation and co-marketing agreement with Beckman Coulter Immunomics - June 2001

Anne De Groot named Core Scientist by Sequella Global TB Foundation and awarded 3 year $900,000 TB vaccine development grant - April 2000

Awarded SBIR Phase I for HIV vaccine development. Full time operations begin. - September 1999

Awarded phase 1 development grant from Rhode Island’s Slater Center for Biomedical Technology - June 1998

EpiVax, Inc. founded by Dr. Anne De Groot - May 1998

September 2009

Open Registration for Spring 2010 URI Class

MTC 594 - Development of Vaccines and Immunotherapeutics (Special Problems in Biotechnology)

Spring 2010 Immunology and Biotherapeutics Seminar at URI

MTC 594 - Special Problems in Biotechnology
Topic: Development of Vaccines and Immunotherapeutics

Instructor: Dr. Anne S. De Groot, M.D.

Days & Times: Wed. 5:00 p.m. -7:45 p.m.

Meeting Dates: 1/25/2010 - 5/3/2010

Location: University of Rhode Island, Providence Campus
(Shepard Building, Room 302)

Address: 80 Washington Street, Providence RI

Prerequisites: graduate standing and permission of chairperson.

For more information:

URI Course Catalog

URI E-Campus Course Schedule

Previous Next